231 related articles for article (PubMed ID: 18541399)
21. The synthesis of a D-glucosamine contrast agent, Gd-DTPA-DG, and its application in cancer molecular imaging with MRI.
Zhang W; Chen Y; Guo DJ; Huang ZW; Cai L; He L
Eur J Radiol; 2011 Sep; 79(3):369-74. PubMed ID: 21106316
[TBL] [Abstract][Full Text] [Related]
22. Stability and trapping of magnetic resonance imaging contrast agents during high-intensity focused ultrasound ablation therapy.
Hijnen NM; Elevelt A; Grüll H
Invest Radiol; 2013 Jul; 48(7):517-24. PubMed ID: 23695082
[TBL] [Abstract][Full Text] [Related]
23. Biodistribution and clearance of liposomal gadolinium-DTPA.
Unger E; Cardenas D; Zerella A; Fajardo LL; Tilcock C
Invest Radiol; 1990 Jun; 25(6):638-44. PubMed ID: 2354925
[TBL] [Abstract][Full Text] [Related]
24. Intraindividual in vivo comparison of gadolinium contrast agents for pharmacokinetic analysis using dynamic contrast enhanced magnetic resonance imaging.
Liang J; Sammet S; Yang X; Jia G; Takayama Y; Knopp MV
Invest Radiol; 2010 May; 45(5):233-44. PubMed ID: 20351653
[TBL] [Abstract][Full Text] [Related]
25. Dynamic contrast-enhanced (DCE) MRI assessment of microvascular characteristics in the murine orthotopic pancreatic cancer model.
Wu L; Lv P; Zhang H; Fu C; Yao X; Wang C; Zeng M; Li Y; Wang X
Magn Reson Imaging; 2015 Jul; 33(6):737-60. PubMed ID: 25169584
[TBL] [Abstract][Full Text] [Related]
26. Simultaneous sustained release of fludarabine monophosphate and Gd-DTPA from an interstitial liposome depot in rats: potential for indirect monitoring of drug release by magnetic resonance imaging.
Port RE; Schuster C; Port CR; Bachert P
Cancer Chemother Pharmacol; 2006 Nov; 58(5):607-17. PubMed ID: 16506037
[TBL] [Abstract][Full Text] [Related]
27. Characterization of tumor angiogenesis with dynamic contrast-enhanced MRI and biodegradable macromolecular contrast agents in mice.
Feng Y; Jeong EK; Mohs AM; Emerson L; Lu ZR
Magn Reson Med; 2008 Dec; 60(6):1347-52. PubMed ID: 19025902
[TBL] [Abstract][Full Text] [Related]
28. [A comparative study of Gd-DTPA and HSA-Gd-DTPA in magnetic resonance lymphography].
Wu YK; Fang TS; Chen DC; Liu GQ; Xu YK
Nan Fang Yi Ke Da Xue Xue Bao; 2007 Oct; 27(10):1597-600. PubMed ID: 17959548
[TBL] [Abstract][Full Text] [Related]
29. MRI contrast enhancement by Gd-DTPA-monoclonal antibody in 9L glioma rats.
Matsumura A; Shibata Y; Nakagawa K; Nose T
Acta Neurochir Suppl (Wien); 1994; 60():356-8. PubMed ID: 7976589
[TBL] [Abstract][Full Text] [Related]
30. Physiologic upper limit of pore size in the blood-tumor barrier of malignant solid tumors.
Sarin H; Kanevsky AS; Wu H; Sousa AA; Wilson CM; Aronova MA; Griffiths GL; Leapman RD; Vo HQ
J Transl Med; 2009 Jun; 7():51. PubMed ID: 19549317
[TBL] [Abstract][Full Text] [Related]
31. Gd-EDDA/HYNIC-RGD as an MR molecular probe imaging integrin alphanubeta3 receptor-expressed tumor-MR molecular imaging of angiogenesis.
Huo T; Du X; Zhang S; Liu X; Li X
Eur J Radiol; 2010 Feb; 73(2):420-7. PubMed ID: 19261416
[TBL] [Abstract][Full Text] [Related]
32. Brain tumor enhancement in magnetic resonance imaging at 3 tesla: intraindividual comparison of two high relaxivity macromolecular contrast media with a standard extracellular gd-chelate in a rat brain tumor model.
Fries P; Runge VM; Bücker A; Schürholz H; Reith W; Robert P; Jackson C; Lanz T; Schneider G
Invest Radiol; 2009 Apr; 44(4):200-6. PubMed ID: 19300099
[TBL] [Abstract][Full Text] [Related]
33. [Renal enhancement and excretion of the hepatobiliary contrast agent Gd-EOB-DTPA].
Zangos S; Hammerstingl R; Mack MG; Straub R; Engelmann K; Eichler K; Balzer T; Vogl TJ
Rofo; 2001 Nov; 173(11):1034-40. PubMed ID: 11704914
[TBL] [Abstract][Full Text] [Related]
34. In vivo near-infrared fluorescence imaging of CD105 expression during tumor angiogenesis.
Yang Y; Zhang Y; Hong H; Liu G; Leigh BR; Cai W
Eur J Nucl Med Mol Imaging; 2011 Nov; 38(11):2066-76. PubMed ID: 21814852
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of [Gd(Bz-TTDA)]2- as a potential contrast agent in MR imaging of the hepatobiliary system: an animal study.
Hsu JS; Jaw TS; Liu GC; Wang YM; Chen SH; Kuo YT; Jao JC; Li CW; Tsai KB
J Magn Reson Imaging; 2004 Oct; 20(4):632-9. PubMed ID: 15390149
[TBL] [Abstract][Full Text] [Related]
36. Contrast-enhanced MR angiography in rats with hepatobiliary contrast agents.
Yoshikawa K; Inoue Y; Shimada M; Akahane M; Itoh S; Seno A; Hayashi S
Magn Reson Imaging; 2004 Sep; 22(7):937-42. PubMed ID: 15288134
[TBL] [Abstract][Full Text] [Related]
37. [Evaluation of Gd-BOPTA and Gd-DTPA in contrast-enhanced MR imaging of the liver].
Zhang HM; Ouyang H; Zhou CW
Zhonghua Zhong Liu Za Zhi; 2006 Feb; 28(2):111-5. PubMed ID: 16750014
[TBL] [Abstract][Full Text] [Related]
38. Assessment of tumor angiogenesis: dynamic contrast-enhanced MRI with paramagnetic nanoparticles compared with Gd-DTPA in a rabbit Vx-2 tumor model.
Kassner A; Thornhill RE; Liu F; Winter PM; Caruthers SD; Wickline SA; Lanza GM
Contrast Media Mol Imaging; 2010; 5(3):155-61. PubMed ID: 20586031
[TBL] [Abstract][Full Text] [Related]
39. Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced MR finding of radiation-induced hepatic injury: relationship to absorbed dose and time course after irradiation.
Okamoto D; Nishie A; Asayama Y; Tajima T; Ishigami K; Kakihara D; Nakayama T; Ohga S; Yoshitake T; Shioyama Y; Honda H
Magn Reson Imaging; 2014 Jul; 32(6):660-4. PubMed ID: 24666574
[TBL] [Abstract][Full Text] [Related]
40. MR imaging of experimental myocardial infarction.
Wikström M
Acta Radiol Suppl; 1992; 379():1-30. PubMed ID: 1317989
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
